


CLAIM AMENDMENTS:

This listing of claims will replace all prior versions and listing of claims in the application.

Listing of the Claims:

Claims 1-4 (cancelled).

Claim 5 (**currently amended**): A compound according to ~~claim 1~~ of the formula IIb:



(IIb)

wherein:

M is -CH- or -N-;

nc is 0, 1 or 2;

R^{2c} is linked to a carbon atom of the 5-membered ring and is selected from hydrogen and methyl;

R^{2d} is linked to a carbon atom of the 6-membered ring and is selected from hydrogen and fluoro;


R^{2a} and R^{2b} are each independently selected from hydrogen, hydroxy, halogeno, cyano, nitro,

trifluoromethyl, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkylsulphanyl, -NR^{3a}R^{4a} (wherein R^{3a} and R^{4a},

which may be the same or different, each represents hydrogen or C₁₋₃alkyl), and Q¹X¹


wherein Q¹ is selected from one of the following groups:

- 1) C₁₋₄alkyl-Q¹³-C(O)-C₁₋₄alkyl-Q¹⁴ wherein Q¹³ and Q¹⁴ are each independently selected from pyrrolidinyl, piperidinyl, piperazinyl,



wherein Q^{1+} is linked to C_{1-6} alkanoyl through a nitrogen atom;

- 2) Q^2 (wherein Q^2 is a 5-6-membered heterocyclic group selected from pyrrolidinyl, piperidinyl, piperazinyl,



which heterocyclic group bears either one substituent selected from methylenedioxy or ethylenedioxy to form a bicyclic ring, or bears at least one substituent selected from C_{2-4} alkanoyl, C_{1-3} alkyl and optionally bears a further 1 or 2 substituents selected from C_{2-5} alkenyl, C_{2-5} alkynyl, C_{1-6} fluoroalkyl, C_{1-6} alkanoyl, C_{2-4} alkanoyl, C_{1-3} alkyl, amino, C_{1-6} alkanoyl, C_{1-4} alkylamino, C_{1-6} alkanoyl, di(C_{1-4} alkyl)amino, C_{1-6} fluoroalkanoyl, carbamoyl, C_{1-4} alkylcarbamoyl, di(C_{1-4} alkyl)carbamoyl, carbamoyl, C_{1-6} alkyl, C_{1-4} alkylcarbamoyl, C_{1-6} alkyl, di(C_{1-4} alkyl)carbamoyl, C_{1-6} alkylsulphonyl, C_{1-6} fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C_{1-4} cyanoalkyl, C_{1-4} alkyl, C_{1-4} hydroxyalkyl, C_{1-4} alkoxy, C_{1-4} alkoxy, C_{1-4} alkyl, C_{1-4} alkylsulphonyl, C_{1-4} alkyl, C_{1-4} alkoxycarbonyl, C_{1-4} aminoalkyl, C_{1-4} alkylamino, di(C_{1-4} alkyl)amino, C_{1-4} alkylamino, C_{1-4} alkyl, di(C_{1-4} alkyl)amino, C_{1-4} alkyl, C_{1-4} alkylamino, C_{1-4} alkoxy, di(C_{1-4} alkyl)amino, C_{1-4} alkoxy and a group $-(O-)_f(C_{1-4}alkyl)_g$ ring D (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C_{1-4} alkyl)); and

- 3) $C_{1-5}alkylQ^2$ (wherein Q^2 is as defined herein);

and X^1 is Oare as defined in claim 1;


and additionally wherein any $C_{1-5}alkyl$ group in Q^1X^1 - which is linked to X^1 may bear one or more substituents selected from hydroxy, halogeno and amino;

Z^a is -O- or -S-;

with the proviso that at least one of R^{2a} and R^{2b} is Q^1X^1 wherein Q^1 and X^1 are as defined herein
 in claim 1;
 or a salt thereof.


Claim 6 (currently amended): A compound according to claim 5 wherein one of R^{2a} and R^{2b} is methoxy and the other is Q^1X^1 wherein X^1 is -O- and Q^1 are as defined in claim 5, is selected from one of the following groups:

1) $C_{1-4}alkyl-Q^{13}-C(O)-C_{1-4}alkyl-Q^{14}$ wherein Q^{13} and Q^{14} are each independently selected from pyrrolidinyl, piperidinyl, piperazinyl,



wherein Q^{14} is linked to $C_{1-6}alkanoyl$ through a nitrogen atom;

2) Q^2 (wherein Q^2 is a 5-6 membered heterocyclic group selected from pyrrolidinyl, piperidinyl, piperazinyl,




which heterocyclic group bears either one substituent selected from methylenedioxy or ethylenedioxy to form a bicyclic ring, or bears at least one substituent selected from $C_{2-4}alkanoylC_{1-3}alkyl$ and optionally bears a further 1 or 2 substituents selected from $C_{2-3}alkenyl$, $C_{2-5}alkynyl$, $C_{1-6}fluoroalkyl$, $C_{1-6}alkanoyl$, $C_{2-4}alkanoylC_{1-3}alkyl$, amino $C_{1-6}alkanoyl$, $C_{1-4}alkylaminoC_{1-6}alkanoyl$, di($C_{1-4}alkyl$)amino $C_{1-6}alkanoyl$, $C_{1-6}fluoroalkanoyl$, carbamoyl, $C_{1-4}alkylcarbamoyl$, di($C_{1-4}alkyl$)carbamoyl, carbamoyl $C_{1-6}alkyl$, $C_{1-4}alkylcarbamoylC_{1-6}alkyl$, di($C_{1-4}alkyl$)carbamoyl $C_{1-6}alkyl$, $C_{1-6}alkylsulphonyl$, $C_{1-6}fluoroalkylsulphonyl$, oxo, hydroxy, halogeno, cyano, $C_{1-4}cyanoalkyl$, $C_{1-4}alkyl$, $C_{1-4}hydroxyalkyl$, $C_{1-4}alkoxy$, $C_{1-4}alkoxyC_{1-4}alkyl$, $C_{1-4}alkylsulphonylC_{1-4}alkyl$, $C_{1-4}alkoxycarbonyl$, $C_{1-4}aminoalkyl$, $C_{1-4}alkylamino$, di(C_{1-4}

~~4alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy and a group $-(O)_f(C_{1-4}alkyl)_g ring D$ (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6 membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C₁₋₄alkyl))~~;

3) C₁₋₅alkylQ² (wherein Q² is as defined herein);

4) C₁₋₄alkylW²C₁₋₄alkylQ² (wherein W² is as defined in claim 1 and Q² is as defined herein);


5) C₁₋₄alkylQ¹⁵(C₁₋₄alkyl)_j(W²)_kQ¹⁶ (wherein W² is as defined in claim 1, j is 0 or 1, k is 0 or 1, and Q¹⁵ and Q¹⁶ are each independently selected from a 5-6 membered heterocyclic group selected from pyrrolidinyl, piperidinyl, piperazinyl,



which heterocyclic group may bear either one substituent selected from methylenedioxy or ethylenedioxy to form a bicyclic ring, or may bear 1, 2 or 3 substituents selected from C₂₋₅alkenyl, C₂₋₅alkynyl, C₁₋₆fluoroalkyl, C₁₋₆alkanoyl, C₂₋₄alkanoylC₁₋₃alkyl, aminoC₁₋₆alkanoyl, C₁₋₄alkylaminoC₁₋₆alkanoyl, di(C₁₋₄alkyl)aminoC₁₋₆alkanoyl, C₁₋₆fluoroalkanoyl, carbamoyl, C₁₋₄alkylcarbamoyl, di(C₁₋₄alkyl)carbamoyl, carbamoylC₁₋₆alkyl, C₁₋₄alkylcarbamoylC₁₋₆alkyl, di(C₁₋₄alkyl)carbamoylC₁₋₆alkyl, C₁₋₆alkylsulphonyl, C₁₋₆fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy and a group $-(O)_f(C_{1-4}alkyl)_g ring D$ (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6 membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from C₁₋₄alkyl), with the proviso one or both of Q¹⁵ and Q¹⁶ must be a 5-6 membered heterocyclic group as defined herein which heterocyclic group bears either one substituent selected from methylenedioxy or ethylenedioxy to form a bicyclic ring, or bears at least one substituent selected from C₂₋₄alkanoylC₁₋₃alkyl and optionally bears 1 or 2 further

substituents selected from those defined herein);

6) $C_{1-4}alkylQ^{15}C_{1-4}alkanoylQ^{16n}$ wherein Q^{15} is as defined herein and Q^{16n} is a 5-6 membered heterocyclic group selected from pyrrolidinyl, piperidinyl, piperazinyl;




wherein Q^{16n} is linked to $C_{1-6}alkanoyl$ through a nitrogen atom and wherein Q^{16n} bears either one substituent selected from methylenedioxy or ethylenedioxy to form a bicyclic ring, or bears 1, 2 or 3 substituents selected from $C_{2-5}alkenyl$, $C_{2-5}alkynyl$, $C_{1-6}fluoroalkyl$, $C_{1-6}alkanoyl$, $C_{2-4}alkanoylC_{1-3}alkyl$, amino $C_{1-6}alkanoyl$, $C_{1-4}alkylaminoC_{1-6}alkanoyl$, di($C_{1-4}alkyl$)amino $C_{1-6}alkanoyl$, $C_{1-6}fluoroalkanoyl$, carbamoyl, $C_{1-4}alkylcarbamoyl$, di($C_{1-4}alkyl$)carbamoyl, carbamoyl $C_{1-6}alkyl$, $C_{1-4}alkylcarbamoylC_{1-6}alkyl$, di($C_{1-4}alkyl$)carbamoyl $C_{1-6}alkyl$, $C_{1-6}alkylsulphonyl$, $C_{1-6}fluoroalkylsulphonyl$, oxo, hydroxy, halogeno, cyano, $C_{1-4}cyanoalkyl$, $C_{1-4}alkyl$, $C_{1-4}hydroxyalkyl$, $C_{1-4}alkoxy$, $C_{1-4}alkoxyC_{1-4}alkyl$, $C_{1-4}alkylsulphonylC_{1-4}alkyl$, $C_{1-4}alkoxycarbonyl$, $C_{1-4}aminoalkyl$, $C_{1-4}alkylamino$, di($C_{1-4}alkyl$)amino, $C_{1-4}alkylaminoC_{1-4}alkyl$, di($C_{1-4}alkyl$)amino $C_{1-4}alkyl$, $C_{1-4}alkylaminoC_{1-4}alkoxy$, di($C_{1-4}alkyl$)amino $C_{1-4}alkoxy$ and a group $-(O)_f(C_{1-4}alkyl)_g$ ring D (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6 membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from $C_{1-4}alkyl$); with the proviso that one or both of Q^{15} and Q^{16n} must be a 5-6 membered heterocyclic group as defined herein which heterocyclic group bears either one substituent selected from methylenedioxy or ethylenedioxy to form a bicyclic ring, or bears at least one substituent selected from $C_{2-4}alkanoylC_{1-3}alkyl$ and optionally bears 1 or 2 further substituents selected from those defined herein;

and additionally wherein any $C_{1-5}alkyl$, $C_{2-5}alkenyl$ or $C_{2-5}alkynyl$ group in Q^1X^1 which is linked to X^1 may bear one or more substituents selected from hydroxy, halogeno and amino).

Claim 7 (original): A compound according to claim 5 wherein one of R^{2a} and R^{2b} is methoxy and the other is Q^1X^1 wherein X^1 is -O- and Q^1 is


C₁₋₄alkyl-Q¹³-C(O)-C₁₋₄alkyl-Q¹⁴ wherein Q¹³ and Q¹⁴ are each independently selected from pyrrolidinyl, piperidinyl, piperazinyl,



wherein Q¹⁴ is linked to C₁₋₆alkanoyl through a nitrogen atom.

Claim 8 (original): A compound according to claim 5 wherein one of R^{2a} and R^{2b} is methoxy and the other is Q¹X¹ wherein X¹ is -O- and Q¹ is selected from one of the following groups:

- 1) Q² (wherein Q² is a 5-6-membered heterocyclic group selected from pyrrolidinyl, piperidinyl, piperazinyl,



which heterocyclic group bears either one substituent selected from methylenedioxy or ethylenedioxy to form a bicyclic ring, or bears one substituent selected from C₂₋₄alkanoylC₁₋₃alkyl; and

- 2) C₁₋₅alkylQ² (wherein Q² is as defined herein).

Claim 9 (original): A compound according to claim 7 or claim 8 wherein R^{2a} is methoxy.

Claim 10 (currently amended): A compound according to claim 5 ~~claim 4~~ selected from:

- 7-{{1-(acetylmethyl)piperidin-4-yl}methoxy}-6-methoxy-4-[(3-methyl-1*H*-indol-5-yl)oxy]quinazoline,
7-{{1-(acetylmethyl)piperidin-4-yl}methoxy}-6-methoxy-4-[(2-methyl-1*H*-indol-6-yl)oxy]quinazoline,
7-{{1-(acetylmethyl)piperidin-4-yl}methoxy}-6-methoxy-4-[(2-methyl-1*H*-indol-5-

yl)oxy]quinazoline,
6-methoxy-4-[(3-methyl-1*H*-indol-5-yl)oxy]-7-{[1-(pyrrolidin-1-ylacetyl)piperidin-4-yl]methoxy}quinazoline,
6-methoxy-4-[(2-methyl-1*H*-indol-6-yl)oxy]-7-{[1-(pyrrolidin-1-ylacetyl)piperidin-4-yl]methoxy}quinazoline,
6-methoxy-4-[(2-methyl-1*H*-indol-5-yl)oxy]-7-{[1-(pyrrolidin-1-ylacetyl)piperidin-4-yl]methoxy}quinazoline,
6-methoxy-4-[(2-methyl-1*H*-indol-5-yl)oxy]-7-[2-(tetrahydro-5*H*-[1,3]dioxolo[4,5-*c*]pyrrol-5-yl)ethoxy]quinazoline,
6-methoxy-4-[(3-methyl-1*H*-indol-5-yl)oxy]-7-[2-(tetrahydro-5*H*-[1,3]dioxolo[4,5-*c*]pyrrol-5-yl)ethoxy]quinazoline,
4-[(2,3-dimethyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-[2-(tetrahydro-5*H*-[1,3]dioxolo[4,5-*c*]pyrrol-5-yl)ethoxy]quinazoline,
4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-[2-(tetrahydro-5*H*-[1,3]dioxolo[4,5-*c*]pyrrol-5-yl)ethoxy]quinazoline,
7-{2-[4-(acetylmethyl)piperazin-1-yl]ethoxy}-4-[(2,3-dimethyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,
7-{2-[4-(acetylmethyl)piperazin-1-yl]ethoxy}-6-methoxy-4-[(3-methyl-1*H*-indol-5-yl)oxy]quinazoline,
7-{2-[4-(acetylmethyl)piperazin-1-yl]ethoxy}-6-methoxy-4-[(2-methyl-1*H*-indol-5-yl)oxy]quinazoline,
7-{2-[4-(acetylmethyl)piperazin-1-yl]ethoxy}-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,
6-methoxy-4-[(2-methyl-1*H*-indol-5-yl)oxy]-7-{2-[4-(pyrrolidin-1-ylacetyl)piperazin-1-yl]ethoxy}quinazoline,
7-{[1-(acetylmethyl)piperidin-4-yl]oxy}-6-methoxy-4-[(2-methyl-1*H*-indol-6-yl)oxy]quinazoline,
7-{[1-(acetylmethyl)piperidin-4-yl]oxy}-6-methoxy-4-[(2-methyl-1*H*-indol-5-yl)oxy]quinazoline, and


7-{{1-(acetylmethyl)piperidin-4-yl}oxy}-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,
and salts or a salt thereof.

Claim 11 (**currently amended**): A compound according to claim 5-claim 4 selected from:

4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-[2-(tetrahydro-5*H*-[1,3]dioxolo[4,5-*c*]pyrrol-5-yl)ethoxy]quinazoline,
7-{{2-[4-(acetylmethyl)piperazin-1-yl]ethoxy}-6-methoxy-4-[(2-methyl-1*H*-indol-5-yl)oxy]quinazoline, and
7-{{2-[4-(acetylmethyl)piperazin-1-yl]ethoxy}-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,
and salts or a salt thereof.


Claim 12 (**currently amended**): A compound according to any one of claims 5, 10 and 11 ~~the preceding claims~~ in the form of a pharmaceutically acceptable salt.

Claim 13 (**currently amended; withdrawn**): A process for the preparation of a compound according to claim 5-claim 4 of the formula I or salt thereof which comprises:
(a) the reaction of a compound of the formula III:



(III)


(wherein R^2 and m are as defined in claim 5-claim 4 and L^1 is a displaceable moiety), with a compound of the formula IV:



(IV)

(wherein ring C, R^1 , Z and n are as defined in claim 5-claim 4) optionally followed by the addition of a substituent on a heterocyclic ring of R^1 or R^2 ;

(b) for compounds of formula I and salts thereof wherein at least one R^2 is R^5X^1 or Q^1X^1 wherein R^5 and Q^1 are as defined in claim 5-claim 4, and X^1 is -O-, -S-, -OC(O)- or -NR¹⁰- (wherein R^{10} independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) the reaction of a compound of the formula V:



(V)


(wherein ring C, Z, R^1 , R^2 and n are as defined in claim 5-claim 4 and X^1 is as defined in this section and s is an integer from 0 to 2) with one of the compounds of the formulae VIa-b:



(wherein R^5 and Q^1 are as defined in claim 5-claim 4 and L^1 is as defined herein);

(c) for compounds of the formula I and salts thereof wherein at least one R^2 is R^5X^1 or Q^1X^1 wherein R^5 and Q^1 are as defined in claim 5-claim 4, and X^1 is -O-, -S-, -OC(O)- or -NR¹⁰- (wherein R^{10} represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) the reaction of a compound

of the formula VII:



(VII)

with one of the compounds of the formulae VIIIa-b:



(wherein R^1 , R^2 , R^5 , Q^1 , ring C, Z and n are as defined in claim 5-claim 4, L^1 and s are as defined herein and X^1 is as defined in this section;

(d) for compounds of the formula I and salts thereof wherein at least one R^2 is R^5X^1 or Q^1X^1 wherein X^1 is as defined in claim 5-claim 4, R^5 is $C_{1-3}alkylR^{113}$, wherein R^{113} is selected from one of the following nine groups:

1) $X^{19}C_{1-3}alkyl$ (wherein X^{19} represents -O-, -S-, -SO₂-, -NR¹¹⁴C(O)- or -NR¹¹⁵SO₂- (wherein R^{114} and R^{115} which may be the same or different are each hydrogen, $C_{1-3}alkyl$ or $C_{1-3}alkoxyC_{2-3}alkyl$);

2) $NR^{116}R^{117}$ (wherein R^{116} and R^{117} which may be the same or different are each hydrogen, $C_{1-3}alkyl$ or $C_{1-3}alkoxyC_{2-3}alkyl$);

3) $X^{20}C_{1-3}alkylX^5R^{22}$ (wherein X^{20} represents -O-, -S-, -SO₂-, -NR¹¹⁸C(O)-, -NR¹¹⁹SO₂- or -NR¹²⁰- (wherein R^{118} , R^{119} , and R^{120} which may be the same or different are each hydrogen, $C_{1-3}alkyl$ or $C_{1-3}alkoxyC_{2-3}alkyl$) and X^5 and R^{22} are as defined in claim 5-claim 4);

4) R^{28} (wherein R^{28} is as defined in claim 5-claim 4);

5) $X^{21}R^{29}$ (wherein X^{21} represents -O-, -S-, -SO₂-, -NR¹²¹C(O)-, -NR¹²²SO₂-, or -NR¹²³-

(wherein R^{121} , R^{122} , and R^{123} which may be the same or different are each hydrogen, $C_{1-3}alkyl$ or $C_{1-3}alkoxyC_{2-3}alkyl$) and R^{29} is as defined in claim 5-claim 4);

6) $X^{22}C_{1-3}alkylR^{29}$ (wherein X^{22} represents -O-, -S-, -SO₂-, -NR¹²⁴C(O)-, -NR¹²⁵SO₂- or -NR¹²⁶- (wherein R¹²⁴, R¹²⁵ and R¹²⁶ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R²⁹ is as defined in claim 5-claim 1);

7) R²⁹ (wherein R²⁹ is as defined in claim 5-claim 1);

8) $X^{22}C_{1-4}alkylR^{28}$ (wherein X^{22} and R²⁸ are as defined in claim 5-claim 1); and

9) $R^{54}(C_{1-4}alkyl)_q(X^9)_rR^{55}$ (wherein q, r, X⁹, R⁵⁴ and R⁵⁵ are as defined in claim 5-claim 1);

Q¹ is C₁₋₅alkylQ²⁷ wherein Q²⁷ is selected from one of the following six groups:

1) Q¹³-C(O)-C₁₋₄alkylQ¹⁴ (wherein Q¹³ and Q¹⁴ are as defined in claim 5-claim 1);

2) W¹Q² (wherein W¹ and Q² are as defined in claim 5-claim 1);


3) Q² (wherein Q² is as defined in claim 5-claim 1);

4) W²C₁₋₄alkylQ² (wherein W² and Q² are as defined in claim 5-claim 1);

5) Q¹⁵(C₁₋₄alkyl)_j(W²)_kQ¹⁶ (wherein W², j, k, Q¹⁵ and Q¹⁶ are as defined in claim 5-claim 1);

6) Q¹⁵C₁₋₄alkanoylQ¹⁶ⁿ (wherein Q¹⁵ and Q¹⁶ⁿ are as defined in claim 5-claim 1);

the reaction of a compound of the formula IX:



(IX)

(wherein X¹, R¹, R², ring C, Z and n are as defined in claim 5-claim 1 and L¹ and s are as defined herein) with one of the compounds of the formulae Xa-b:

R¹¹³-H (Xa)

Q²⁷-H (Xb)

(wherein R¹¹³ and Q²⁷ are as defined herein) optionally followed by the addition of a substituent on a heterocyclic ring of R¹ or R²;

and when a salt of a compound of formula I is required, reaction of the compound obtained with an acid or base whereby to obtain the desired salt.

Claim 14 (**currently amended**): A pharmaceutical composition which comprises a compound of the formula IIb ~~formula I~~ as defined in claim 5 ~~claim 1~~ or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier.

Claim 15 (**cancelled**)

Claim 16 (**currently amended; withdrawn**): A method for producing an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula IIb ~~formula I~~ as defined in claim 5 ~~claim 1~~ or a pharmaceutically acceptable salt thereof.